AVAPRITINIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H27FN10
Molecular Weight	498.558
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C=C(C=N1)C2=CN3N=CN=C(N4CCN(CC4)C5=NC=C(C=N5)[C@@](C)(N)C6=CC=C(F)C=C6)C3=C2

InChI

InChIKey=DWYRIWUZIJHQKQ-SANMLTNESA-N

InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H27FN10
Molecular Weight	498.558
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.bloodjournal.org/content/126/23/568?sso-checked=true

AVAPRITINIB (Blu-285) is a potent and selective inhibitor for hematologic malignancies with KIT Exon 17 Mutations. BLU-285 has demonstrated biochemical in vitro activity on the KIT exon-17 mutant enzyme, KIT D816V. Cellular activity of BLU-285 on KIT D816 mutants was measured by autophosphorylation in the human mast cell leukemia cell line HMC1.2, and the P815 mouse mastocytoma cell line with IC50= 4 and 22 nM, respectively. In vivo BLU-285 was well tolerated and has demonstrated dose-dependent antitumor efficacy. Complete tumor growth inhibition and ≥ 75% KIT kinase inhibition was observed with 10 mg/kg once daily, oral dosing of BLU-285 in the aggressive KIT exon 17 mutant driven P815 mastocytoma model grown as a solid tumor allograft as well as in a disseminated model of the disease. BLU-285 was also well tolerated in this in vivo model and had no adverse effects on body weight at either dose.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Stem cell growth factor receptor 57 Target ID: CHEMBL1936 Sources: http://www.bloodjournal.org/content/126/23/568?sso-checked=true	Inhibitor 8504		0.27 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Gastrointestinal stromal tumor 20 Sources: https://clinicaltrials.gov/ct2/show/NCT02508532	Primary	Phase I 438	Unknown Approved Use Unknown
Aggressive systemic mastocytosis 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02561988	Primary	Phase I 438	Unknown Approved Use Unknown
Mast cell leukemia 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02561988	Primary	Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
813 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AVAPRITINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
15400 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AVAPRITINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
57 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AVAPRITINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AVAPRITINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY445271	https://www.001chemical.com/chem/1703793-34-3
AA Blocks	AA01DQ80	https://www.aablocks.com/goods/Goods/detail?id=AA01DQ80
abcr GmbH	AB534401	http://www.abcr.com/shop/en/AB534401
Acorn PharmaTech	ACN-051245	http://www.acornpharmatech.com/
Ark Pharm	AK00739613	http://www.arkpharminc.com/products/1703793-34-3.html
Ark Pharma Scientific Limited	A-1558	http://www.arkpharmtech.com/product/33509.html
Chem Scene	CS-7577	http://www.chemscene.com/1703793-34-3.html
Chemspace	CSSB00102462676	https://chem-space.com/CSSB00102462676
DC Chemicals	DC10530	http://www.dcchemicals.com/product_show-Avapritinib.html
eNovation Chemicals	D589727	https://www.enovationchem.com/ProductDetails.asp?ProductID=D589727
eNovation Chemicals	Y0975761	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975761
Excenen	EX-A1366	http://www.excenen.com/searchresultlist.php?id=1703793-34-3
MedChem Express	HY-101561	https://www.medchemexpress.com/BLU-285.html
Molcore	MC445271	https://www.molcore.com/product/1703793-34-3
Selleck Chemicals	S8553	http://www.selleckchem.com/products/blu-285.html
Smolecule	S519817	http://www.smolecule.com/products/s519817
THE BioTek	bt-261044	https://www.thebiotek.com/product/inhibitors/bt-261044

PubMed

Title	Date	PubMed
BLU-285, DCC-2618 Show Activity against GIST.	2017 Feb	28077435

Patents

Sample Use Guides

In Vivo Use Guide

BLU-285 capsules or tablets for oral administration. BLU-285 will be dosed daily for 28 day cycles.

Route of Administration: Oral

In Vitro Use Guide

Cellular activity of BLU-285 on KIT D816 mutants was measured by autophosphorylation in the human mast cell leukemia cell line HMC1.2, and the P815 mouse mastocytoma cell line with IC50= 4 and 22 nM, respectively.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:38:47 GMT 2025` Edited by `admin` on `Mon Mar 31 23:38:47 GMT 2025`
Record UNII	513P80B4YJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AYVAKIT

Preferred Name

English

AVAPRITINIB

Official Name

English

X-720776

Code

English

70C366

Code

English

AVAPRITINIB [MI]

Common Name

English

C-366

Code

English

(S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-4-YL)PIPERAZIN-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE

Systematic Name

English

AVAPRITINIB [ORANGE BOOK]

Common Name

English

5-PYRIMIDINEMETHANAMINE, .ALPHA.-(4-FLUOROPHENYL)-.ALPHA.-METHYL-2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-4-YL)-1-PIPERAZINYL)-, (.ALPHA.S)-

Systematic Name

English

Avapritinib [WHO-DD]

Common Name

English

BLU-285

Code

English

X720776

Code

English

avapritinib [INN]

Common Name

English

AVAPRITINIB [USAN]

Common Name

English

(1S)-1-(4-Fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

506515